Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults
Open Access
- 17 July 2015
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Vaccines
- Vol. 3 (4), 97-108
- https://doi.org/10.1177/2051013615595595
Abstract
Flublok is the first recombinant hemagglutinin (HA) vaccine licensed by the US Food and Drugs Administration for the prevention of influenza in adults aged 18 and older. The HA proteins produced in insect cell culture using the baculovirus expression system technology are exact analogues of wild type circulating influenza virus HAs. The universal HA manufacturing process that has been successfully scaled to the 21,000L contributes to rapid delivery of a substantial number of doses. This review discusses the immunogenicity, efficacy and safety data from five pivotal clinical studies used to support licensure of trivalent Flublok for adults 18 years of age and older in the United States. The trial data demonstrate that the higher antigen content in Flublok results in improved immunogenicity. Data further suggest improved efficacy and a slightly lower local reactogenicity compared with standard inactivated influenza vaccine, despite the presence of more antigen (statistically significant). Flublok influenza vaccine can include HAs designed to mimic ‘drift’ in influenza viruses as the process of predicting antigenic drift advances and, at a minimum, could address late appearing influenza viruses. The implementation of the latter will require support from regulatory authorities.Keywords
This publication has 37 references indexed in Scilit:
- Effectiveness of Seasonal Influenza Vaccines against Influenza-Associated Illnesses among US Military Personnel in 2010–11: A Case-Control ApproachPLOS ONE, 2012
- Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trialVaccine, 2011
- A fast track influenza virus vaccine produced in insect cellsJournal of Invertebrate Pathology, 2011
- Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age☆Vaccine, 2011
- Clinical Efficacy of Cell Culture–Derived and Egg‐Derived Inactivated Subunit Influenza Vaccines in Healthy AdultsClinical Infectious Diseases, 2010
- Comparative Efficacy of Inactivated and Live Attenuated Influenza VaccinesNew England Journal of Medicine, 2009
- Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete exampleBMC Infectious Diseases, 2009
- Component‐Specific Effectiveness of Trivalent Influenza Vaccine as Monitored through a Sentinel Surveillance Network in Canada, 2006–2007The Journal of Infectious Diseases, 2009
- Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004–2005 Season to the 2006–2007 SeasonThe Journal of Infectious Diseases, 2009
- Safety and Immunogenicity of a Baculovirus-Expressed Hemagglutinin Influenza VaccineJAMA, 2007